BioNTech SE American Depositary Share (BNTX)

About BNTX

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

7,807

Website

www.biontech.com/

Fundamentals

1-day range

$98.84$105.23

Market cap

$23.18B

P/E (trailing)

—

P/E (forward)

-18.02

EPS (trailing)

$-6.71

Dividend yield

—

Beta

1.27

Avg. volume

1.18M

Ex-dividend date

June 2, 2022

Dividend pay date

June 17, 2022

Forecasts

20 analyst ratings

BioNTech SE American Depositary Share Competitors

Chosen by industry and closest market cap.

• BNTX

  BioNTech SE American Depositary Share

  $102.04

  ▼ 8.40%
  Market cap $23.18BP/E —
  $79.52$124
• MRNA

  Moderna Inc. Common Stock

  $137.93

  ▼ 3.39%
  Market cap $21.88BP/E —
  $22.28$176.66
• HALO

  Halozyme Therapeutics Inc. Common Stock

  $105.33

  ▼ 1.49%
  Market cap $9.76BP/E 27.63
  $61.23$109.66
• QGEN

  Qiagen N.V. Common Shares

  $43.12

  ▼ 1.43%
  Market cap $8.72BP/E 22.14
  $32.53$57.82
• KYMR

  Kymera Therapeutics Inc. Common Stock

  $118.08

  ▼ 1.79%
  Market cap $8.25BP/E —
  $39.84$130.05
• RVMD

  Revolution Medicines Inc. Common Stock

  $207.89

  ▼ 6.00%
  Market cap $38.79BP/E —
  $35.64$224.31
• CRSP

  CRISPR Therapeutics AG Common Shares

  $57.69

  ▼ 2.84%
  Market cap $4.78BP/E —
  $44.12$78.48

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More
  SeekingAlpha · 8/28/2026
• BioNTech Stock Dips After BNT122-01 Trial Termination
  Benzinga · 8/28/2026
• BioNTech Says It Will Terminate Phase 2 BNT122-01 Trial Of Autogene Cevumeran In ctDNA-Positive Resected Colorectal Cancer After DSMB Identified Numerical Overall Survival Imbalance Between Arms; No New Safety Signals
  Benzinga · 8/28/2026
• QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
  benzinga · 8/27/2026
• QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
  Benzinga · 8/27/2026
• FDA Approves Pfizer And BioNTech's Supplemental Biologics License Application For 2026-2027 COVID-19 Vaccine Formula
  Benzinga · 8/27/2026
• Don't Sleep On Software
  SeekingAlpha · 8/25/2026
• Why Is Arbutus Biopharma Stock Gaining Friday?
  Benzinga · 8/21/2026
• Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
  SeekingAlpha · 8/20/2026

• Zapata Gomez Ramon · May 12, 2026 · Grant

  15.1K
• Zapata Gomez Ramon · May 12, 2026 · Grant

  18.9K
• Jimenez Kylie · May 12, 2026 · Grant

  8.4K
• Jimenez Kylie · May 12, 2026 · Grant

  10.5K
• Ryan James Timothy Patrick · May 12, 2026 · Grant

  10.1K
• Ryan James Timothy Patrick · May 12, 2026 · Grant

  12.6K
• Hanekamp Annemarie · May 12, 2026 · Grant

  10.1K
• Hanekamp Annemarie · May 12, 2026 · Grant

  12.6K
• Poetting Sierk · May 12, 2026 · Grant

  10.1K
• Poetting Sierk · May 12, 2026 · Grant

  12.6K
• Poetting Sierk · April 22, 2026 · Sale

  50.0K @ $110.56

Institutional Ownership

March 31, 2026

Total shares held

49.63M

Total value held

$3.81B

Institutional holders

272